Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for the third quarter of 2024 before markets open on November 7, 2024.
Aurinia’s management team will host a conference call and webcast at 8:30 am ET that day to review these results and provide a general business update.
Webcast & Conference Call Details
The link to the audio webcast is availablehere. To join the conference call, please dial (800) 715-9871 / +1 (646) 307-1963. Conference ID: 6251719 or company name required for entry. A replay of the webcast will be available on Aurinia’s website.
About Aurinia
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS®(voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a differentiated, potential best-in-class therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand).
View source version on businesswire.com:https://www.businesswire.com/news/home/20241030222492/en/
Media & Investor Inquiries:Andrea ChristopherCorporate Communications & Investor RelationsAurinia Pharmaceuticals Inc.achristopher@auriniapharma.comGeneral Investor Inquiries:ir@auriniapharma.com
Source: Aurinia Pharmaceuticals Inc.
Released October 30, 2024